Sandip Prasad, MD, MPhil

GU Oncology Now

Sandip Prasad, MD, MPhil, of Garden State Urology, Atlantic Health System, provides an overview of the differences between <a href="https://guoncologynow.com/post/atlas-envision-trials-demonstrate-benefit-of-ugn-102-for-nmibc" target="_blank" rel="noopener">ATLAS and ENVISION</a>, shares the treatment-related adverse events associated with UGN-102 in both studies, and opines on whether the data are strong enough to make UGN-102 a practice-changing alternative to TURBT for intermediate-risk, low-grade non-muscle invasive bladder cancer (NMIBC).Do the <a href="https://guoncologynow.com/post/ugn-102-may-be-superior-to-turbt-for-managing-low-grade-intermediate-risk-nmibc" target="_blank" rel="noopener">results of ATLAS</a> suggest that UGN-102 is a superior therapeutic alternative to TURBT for intermediate-risk, low-grade NMIBC? Dr. Prasad suggests that this is the &ldquo;hallmark question&rdquo; and points to the reported tumor-free complete response after 3 months of treatment as well as the estimated probability of disease-free survival after 15 months to make his case.Further updates are expected from the ENVISION trial in 2024. Reported topline data suggest that patients treated with UGN-102 had a 79.2% rate of complete response after 3 months of treatment.

Dr. Sandip Prasad on ATLAS and ENVISION for Intermediate-Risk, Low-Grade NMIBC

Non-Muscle Invasive Urothelial Carcinoma

Dr. Prasad provides an overview of the differences between ATLAS and ENVISION and opines on whether UGN-102 is a practice-changing alternative to TURBT.

Dr. Sandip Prasad on ATLAS, ENVISION for Low-Grade NMIBC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe